
Akumin AKU
Quarterly report 2023-Q3
added 12-12-2023
Akumin Deferred Revenue 2011-2026 | AKU
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Akumin
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 7.53 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.53 M | 7.53 M | 7.53 M |
Deferred Revenue of other stocks in the Diagnostics research industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
1.34 M | - | -6.23 % | $ 30.6 M | ||
|
Anixa Biosciences
ANIX
|
1.19 M | $ 3.03 | -2.26 % | $ 98.3 K | ||
|
Aspira Women's Health
AWH
|
489 K | - | -6.19 % | $ 10.5 M | ||
|
Castle Biosciences
CSTL
|
6.62 M | $ 39.83 | 1.7 % | $ 1.11 B | ||
|
Brainsway Ltd.
BWAY
|
1.54 M | $ 23.52 | -2.2 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
143 M | $ 34.0 | 0.68 % | $ 366 M | ||
|
Accelerate Diagnostics
AXDX
|
547 K | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
4.14 M | $ 102.43 | 0.13 % | $ 19 B | ||
|
Fulgent Genetics
FLGT
|
2.23 M | $ 26.13 | -0.44 % | $ 790 M | ||
|
BioNano Genomics
BNGO
|
1.13 M | $ 1.3 | -11.56 % | $ 1.65 M | ||
|
Guardant Health
GH
|
35.5 M | $ 111.99 | 1.37 % | $ 13.7 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
19 K | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
1.61 M | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
362 K | - | - | $ 79.8 M | ||
|
Danaher Corporation
DHR
|
1.3 B | $ 218.32 | -0.59 % | $ 160 B | ||
|
DermTech
DMTK
|
196 K | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
132 K | $ 66.61 | -0.1 % | $ 4.61 B | ||
|
Global Cord Blood Corporation
CO
|
458 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
13.5 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
77.3 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
8.42 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
733 M | - | - | $ 10.7 B | ||
|
DexCom
DXCM
|
18.4 M | $ 73.22 | -1.05 % | $ 28.3 B | ||
|
NeoGenomics
NEO
|
409 K | $ 11.91 | -3.95 % | $ 1.51 B | ||
|
CareDx, Inc
CDNA
|
4.75 M | $ 20.33 | -2.26 % | $ 1.09 B | ||
|
DarioHealth Corp.
DRIO
|
997 K | $ 10.14 | -1.55 % | $ 288 M | ||
|
Enzo Biochem
ENZ
|
2.68 M | - | -8.98 % | $ 14.8 K | ||
|
Personalis
PSNL
|
3.1 M | $ 9.27 | -7.02 % | $ 549 M | ||
|
Heska Corporation
HSKA
|
5.08 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
185 K | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
260 M | $ 144.04 | -3.77 % | $ 22.9 B | ||
|
QIAGEN N.V.
QGEN
|
57.1 M | - | - | $ 10.6 B | ||
|
IQVIA Holdings
IQV
|
1.78 B | $ 229.24 | -2.71 % | $ 41.6 B | ||
|
Charles River Laboratories International
CRL
|
248 M | $ 208.45 | -1.53 % | $ 10.7 B | ||
|
Thermo Fisher Scientific
TMO
|
2.85 B | $ 575.61 | -2.79 % | $ 220 B | ||
|
Trinity Biotech plc
TRIB
|
4.44 M | $ 0.81 | -7.96 % | $ 61.9 M | ||
|
Twist Bioscience Corporation
TWST
|
6.88 M | $ 40.92 | -1.59 % | $ 2.45 B | ||
|
Medpace Holdings
MEDP
|
711 M | $ 581.54 | -1.94 % | $ 18 B | ||
|
Biodesix
BDSX
|
678 K | $ 9.61 | -0.57 % | $ 1.25 B | ||
|
Precipio
PRPO
|
110 K | $ 24.39 | 0.54 % | $ 31.7 M | ||
|
Laboratory Corporation of America Holdings
LH
|
392 M | $ 269.91 | 0.04 % | $ 22.6 B | ||
|
Mettler-Toledo International
MTD
|
122 M | $ 1 376.67 | -1.16 % | $ 29.2 B | ||
|
ICON Public Limited Company
ICLR
|
1.61 B | $ 179.26 | -3.57 % | $ 14.8 B | ||
|
IDEXX Laboratories
IDXX
|
33.8 M | $ 673.4 | -0.49 % | $ 55.5 B |